OraQuick(R) In-Home HIV Test Named a "Best Invention of 2012" by TIME Magazine

OraQuick(R) In-Home HIV Test Named a "Best Invention of 2012" by TIME Magazine

First and Only In-Home Rapid Oral HIV Test Recognized as a Top Innovation of
the Year

BETHLEHEM, Pa., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) today announced the company's OraQuick^® In-Home HIV Test, the
first ever in-home rapid infectious disease test made available directly to
consumers, has been named one of the "Best Inventions of 2012" by TIME. The
OraQuick^® In-Home HIV Test is the only health innovation included on this
prestigious list for 2012.

"With just a swab of saliva and 20 minutes, OraQuick^® can identify the
antibodies that signal HIV infection," TIME reported in its annual story on
the most important inventions of the year. This is the second such recognition
for OraSure from TIME, as the OraQuick^® ADVANCE HIV 1/2 Antibody professional
test was honored in 2004. At that time, the U.S. Food and Drug Administration
(FDA) approved the first oral fluid rapid HIV test for health care
professionals and this year, the same proven technology was made available for
consumers to use at home.

"The OraQuick^® In-Home HIV Test is a breakthrough product in the fight
against HIV and AIDS because it empowers more people to learn their HIV status
in the comfort and privacy of their own homes," said Douglas A. Michels,
President and Chief Executive Officer of OraSure Technologies. "OraSure is
extremely proud to be recognized by TIME for this innovation."

The OraQuick^® In-Home HIV Test, approved by the U.S. Food and Drug
Administration (FDA) in July 2012, detects antibodies to both HIV-1 and HIV-2
with an oral swab, providing a confidential in-home testing option with
results in as little as 20 minutes. The in-home test, which is now available
at major retailers nationwide, is an over-the-counter version of OraQuick
ADVANCE^®, an oral swab rapid test with more than 25 million units sold in the
professional market, including doctors, hospitals, clinics and other trained
professionals. The OraQuick In-Home HIV Test is available at thousands of
retailers nationwide and online at OraQuick.com.

To ensure optimal support for individuals using the OraQuick^® In-Home HIV
Test, OraSure offers live support and comprehensive referral services 24 hours
a day, seven days a week, every day of the year, through a toll-free support
center and comprehensive consumer website. The OraQuick^® Support Center is
staffed with highly trained, bi-lingual (English/Spanish) representatives who
are available by telephone at 866-436-6527 to answer questions about HIV/AIDS
and using and interpreting the test. They also provide referrals to follow-up
and care, and can take orders for the OraQuick In-Home HIV Test. Additionally,
the product website provides access to resources and referral to follow-up
counseling, confirmatory testing and medical care.

Visit OraQuick.com for more information.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick^® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market – making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440

Important Information Regarding the OraQuick In-Home HIV Test - You must be 17
or older to use this test.A positive result with this test does not mean that
you are definitely infected with HIV, but rather that additional testing
should be done in a medical setting. A negative result with this test does not
mean that you are definitely not infected with HIV, particularly when exposure
may have been with in the previous three months. If your test is negative and
you engage in activities that put you at risk for HIV on a regular basis, you
should test regularly. This product should not be used to make decisions on
behavior that may put you at increased risk for HIV.

CONTACT: Investor Contact:
         Ronald H. Spair
         Chief Financial Officer
         610-882-1820
         investorinfo@orasure.com
        
         Media Contact:
         Ashley Buford
         GolinHarris for OraSure Technologies
         917-653-5694
         abuford@golinharris.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.